Biologic safety in psoriasis: review of long-term safety data.

  title={Biologic safety in psoriasis: review of long-term safety data.},
  author={Yasaman Mansouri and Gary Goldenberg},
  journal={The Journal of clinical and aesthetic dermatology},
  volume={8 2},
The development of targeted biologic agents has revolutionized the treatment of psoriasis. In this review, the authors focus on the published long-term (≥ one year) safety data for the use of tumor necrosis factor-α antagonists etanercept, infliximab, and adalimumab, as well as the IL-12/IL-23 antagonist ustekinumab, in adult patients with moderate-to-severe psoriasis. The efficacy of these currently available biologic therapies has been demonstrated in several studies, and their safety… CONTINUE READING